465 related articles for article (PubMed ID: 30723876)
1. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
Eljaaly K; Alharbi A; Alshehri S; Ortwine JK; Pogue JM
Drugs; 2019 Feb; 79(3):243-269. PubMed ID: 30723876
[TBL] [Abstract][Full Text] [Related]
2. Plazomicin: A Next-Generation Aminoglycoside.
Shaeer KM; Zmarlicka MT; Chahine EB; Piccicacco N; Cho JC
Pharmacotherapy; 2019 Jan; 39(1):77-93. PubMed ID: 30511766
[TBL] [Abstract][Full Text] [Related]
3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
4. Once-Daily Plazomicin for Complicated Urinary Tract Infections.
Wagenlehner FME; Cloutier DJ; Komirenko AS; Cebrik DS; Krause KM; Keepers TR; Connolly LE; Miller LG; Friedland I; Dwyer JP;
N Engl J Med; 2019 Feb; 380(8):729-740. PubMed ID: 30786187
[TBL] [Abstract][Full Text] [Related]
5. Plazomicin: an investigational therapy for the treatment of urinary tract infections.
Karaiskos I; Souli M; Giamarellou H
Expert Opin Investig Drugs; 2015; 24(11):1501-11. PubMed ID: 26419762
[TBL] [Abstract][Full Text] [Related]
6. Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections.
Bilinskaya A; Linder KE; Kuti JL
Expert Rev Anti Infect Ther; 2020 Aug; 18(8):705-720. PubMed ID: 32319833
[TBL] [Abstract][Full Text] [Related]
7. A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.
Connolly LE; Riddle V; Cebrik D; Armstrong ES; Miller LG
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378708
[TBL] [Abstract][Full Text] [Related]
8. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.
Denervaud-Tendon V; Poirel L; Connolly LE; Krause KM; Nordmann P
J Antimicrob Chemother; 2017 Oct; 72(10):2787-2791. PubMed ID: 29091226
[TBL] [Abstract][Full Text] [Related]
9. Expected plazomicin susceptibility in India based on the prevailing aminoglycoside resistance mechanisms in Gram-negative organisms derived from whole-genome sequencing.
Pragasam AK; Jennifer SL; Solaimalai D; Muthuirulandi Sethuvel DP; Rachel T; Elangovan D; Vasudevan K; Gunasekaran K; Veeraraghavan B
Indian J Med Microbiol; 2020; 38(3 & 4):313-318. PubMed ID: 33154241
[TBL] [Abstract][Full Text] [Related]
10.
Castanheira M; Davis AP; Mendes RE; Serio AW; Krause KM; Flamm RK
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866862
[TBL] [Abstract][Full Text] [Related]
11. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms.
Castanheira M; Deshpande LM; Woosley LN; Serio AW; Krause KM; Flamm RK
J Antimicrob Chemother; 2018 Dec; 73(12):3346-3354. PubMed ID: 30219857
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
Zhang Y; Kashikar A; Bush K
J Antimicrob Chemother; 2017 Oct; 72(10):2792-2795. PubMed ID: 29091224
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
Zhanel GG; Lawson CD; Zelenitsky S; Findlay B; Schweizer F; Adam H; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Expert Rev Anti Infect Ther; 2012 Apr; 10(4):459-73. PubMed ID: 22512755
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
Martins AF; Bail L; Ito CAS; da Silva Nogueira K; Dalmolin TV; Martins AS; Rocha JLL; Serio AW; Tuon FF
Diagn Microbiol Infect Dis; 2018 Mar; 90(3):228-232. PubMed ID: 29223516
[TBL] [Abstract][Full Text] [Related]
16. Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae.
Thwaites M; Hall D; Stoneburner A; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C
Diagn Microbiol Infect Dis; 2018 Dec; 92(4):338-345. PubMed ID: 30097297
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of plazomicin against quinolone-resistant gram-negative bacteria isolated from catheter-associated urinary tract infections.
Abd-Elmonsef MME; Nagla S; Afandy ME; Maxwell SY
J Chemother; 2021 Nov; 33(7):462-468. PubMed ID: 33810779
[TBL] [Abstract][Full Text] [Related]
18. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043
[TBL] [Abstract][Full Text] [Related]
19. Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes.
Cox G; Ejim L; Stogios PJ; Koteva K; Bordeleau E; Evdokimova E; Sieron AO; Savchenko A; Serio AW; Krause KM; Wright GD
ACS Infect Dis; 2018 Jun; 4(6):980-987. PubMed ID: 29634241
[TBL] [Abstract][Full Text] [Related]
20. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
